Vimarsana
Biggest News Aggregation in the World

Page 2 - Discussion Session News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Discussion Session. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Discussion Session Today - Breaking & Trending Today

Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - Vimarsana News

Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

27.04.2023 - SHANGHAI, China and REDWOOD CITY, Calif., April 27, 2023 (GLOBE NEWSWIRE) - Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that data ... Seite 1

AGENUS INC. : Stock Market News and Information | AGEN| US00847G7051 - Vimarsana News

AGENUS INC. : Stock Market News and Information | AGEN| US00847G7051

AGENUS INC. : News, information and stories for AGENUS INC. | Nasdaq: AGEN | Nasdaq

Astellas Highlights Data on Advanced and Rare Cancers during 2022 ASCO Annual Meeting and EHA 2022 Hybrid Congress - Vimarsana News

Astellas Highlights Data on Advanced and Rare Cancers during 2022 ASCO Annual Meeting and EHA 2022 Hybrid Congress

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") will share new research during the 2022 American Society...

Activist lauds gov't, DPR for sexual violence bill - Vimarsana News

Activist lauds gov't, DPR for sexual violence bill

Migrant Care lauds the government and the House of Representatives for drafting the Law on Sexual Violence Crime as a legal basis for victims' ...

Germline genetic testing can benefit all cancer patients as a routine practice in cancer care - Vimarsana News

Germline genetic testing can benefit all cancer patients as a routine practice in cancer care

Germline genetic testing can benefit all cancer patients as a routine practice in cancer care -- New data to be presented at 2021 ASCO Annual Meeting highlight need for increased germline testing in all cancer patients regardless of medical policy -- News provided by Share this article Share this article SAN FRANCISCO, May 25, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, is presenting multiple studies in multiple cancer types at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting showing all cancer patients can benefit from germl...